Moderna Stock No-Brainer After FDA Win: Buy or Not?
A recent FDA decision sparked a powerful rally in Moderna shares, but is the move enough to call it a no-brainer? Thi...
This article compares withdrawal strategies using multi-asset portfolios versus the SP 500, highlighting risk, diversification, and potential retirement outcomes.
23,797 articlesA recent FDA decision sparked a powerful rally in Moderna shares, but is the move enough to call it a no-brainer? Thi...
A Sioux Falls crypto investor faces 29 federal counts in a scheme prosecutors say used eight entities and new investo...
A private defense contractor is pushing the Navy toward autonomous, unmanned surface ships. This article explains the...
Analysts are arguing that Merck's sac-TMT program could unlock substantial upside for MRK, supported by a strong pipe...
Bank of America raises NVIDIA's price target to $320, backing the move with a brighter view of a $1.7 trillion AI dat...
CoreWeave reported a $740 million quarterly loss as it stacked up a record backlog and a massive Meta deal, underscor...
Could MaxLinear be the next stock to 10x? This guide breaks down the company, its AI hardware niche, and the realisti...
Intel reached a fresh 52-week high as its foundry strategy gains traction and data-center demand strengthens. The sto...
Memory prices still skyrocketing have traders eyeing a new phase for Micron, SanDisk, and SK Hynix amid lingering sup...
Rivian is targeting a major production shift with the R2 lineup. This guide weighs the bull and bear cases for rivian...
Despite a 2026 pullback, Advanced Micro Devices still shows fundamental strength in data-center AI demand and a diver...
Discover how NVIDIA stands at the center of the AI revolution, what to watch in its business, and how to assess the i...